<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Christine Aylward on Medium]]></title>
        <description><![CDATA[Stories by Christine Aylward on Medium]]></description>
        <link>https://medium.com/@c_aylward?source=rss-93033e4b53e7------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*_tfH8AgL3qLs54McXauDQQ.png</url>
            <title>Stories by Christine Aylward on Medium</title>
            <link>https://medium.com/@c_aylward?source=rss-93033e4b53e7------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Fri, 20 Nov 2026 11:33:56 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@c_aylward/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Paradigm Shift: 4 New Partnerships Expand Global Clinical Trial Access]]></title>
            <link>https://medium.com/@c_aylward/paradigm-shift-4-new-partnerships-expand-global-clinical-trial-access-84ab0f2c3568?source=rss-93033e4b53e7------2</link>
            <guid isPermaLink="false">https://medium.com/p/84ab0f2c3568</guid>
            <dc:creator><![CDATA[Christine Aylward]]></dc:creator>
            <pubDate>Sat, 14 Dec 2024 17:07:17 GMT</pubDate>
            <atom:updated>2024-12-14T17:07:17.149Z</atom:updated>
            <content:encoded><![CDATA[<p><strong><em>“Most patients with cancer receive their care through community settings. Despite studies indicating that more than 70% of patients are willing to participate in clinical trials, fewer than 5% of patients with cancer receive </em>treatment within the context of a clinical trial.” — Barriers to Clinical Trial Implementation, JAMA Network.</strong></p><p><strong>Despite the fact that $2 billion is spent annually on patient recruitment for clinical trials, approximately 80% of clinical trials are delayed or closed due to problems with recruitment.</strong> Improvements in clinical trial administration — from data collection to recruitment — can dramatically accelerate the delivery of life saving treatments to patients, especially in underserved communities. This is why we invested in <a href="https://www.paradigm.inc/">Paradigm</a>.</p><p>Pardigm’s mission is to reduce clinical trial burden and expand patient access to the best possible care by increasing patient enrollment, improving screening access using ML models, accelerating global trials, improving diversity and inclusion, and expanding patient access.</p><p>Since inception in 2023, Paradigm has been building a robust ecosystem of leading health centers. They recently announced four strategic partnerships that significantly expand their reach domestically and globally. Paradigm recent strategic partnerships:</p><ul><li><strong>Japan’s </strong><a href="https://www.ncc.go.jp/en/index.html"><strong>National Cancer Center</strong></a>, one of the most prestigious institutions in Japan. This partnership extends the global presence to expand and democratize access to cancer clinical trials across Japan. The National Cancer Center Hospital East conducts more than 500 clinical trials annually and leads Japan’s largest cancer genomic screening network called LC-SCRUM-Asia across more than 150 hospitals. Paradigm will streamline clinical trial operations nationwide, making it easier for global pharmaceutical companies to include Japanese clinical trial sites.</li><li><a href="https://nycancer.com/"><strong>New York Cancer &amp; Blood Specialists</strong></a><strong> (NYCBS)</strong>, one of the largest and most respected oncology networks. NYCBS brings 64 world class cancer care centers directly to local communities, sparing patients difficult travel during their cancer treatments. Paradigm is expanding the capacity and efficiency of NYCBS’ clinical trial and research program to ensure that more patients can access life-saving therapies without the barriers of extensive travel or switching providers.</li><li><a href="https://www.shebaonline.org/"><strong>Sheba Medical Center</strong></a>, Israel’s largest hospital, and ARC Innovation. This partnership will expand the reach and efficiency of all of Sheba’s related clinics by streamlining operations, patient screening, recruitment, and data collection. Sheba is a widely used site for biopharma clinical trials and Israel is considered one of the most sophisticated and technology-advanced healthcare systems in the world.</li><li><a href="https://flcancer.com/"><strong>Florida Cancer Specialists and Research Institute</strong></a> (FCS) has 33 early and late-stage research locations and serves more than 3.4 million patients a year. FCS will deploy Paradigm’s technology platform to expand patient access to clinical trials as a care option. For biopharma trial sponsors, this partnership will enable trials to be conducted at scale across Florida, which includes a more diverse patient population.</li></ul><p><strong>Magnetic’s Perspective: </strong>At <a href="https://magneticvc.com/">Magnetic Ventures</a>, we identified clinical trial improvement through AI advances as a major priority for the portfolio. Our investment thesis that industry disruption across the healthcare ecosystem occurs through advances in technology continues to prove its merit. Paradigm was recently <a href="https://openai.com/index/paradigm/">highlighted by OpenA</a>I for the company’s innovation in using GPT-4 to improve patient access to clinical trials. In this case study, Paradigm’s generative AI approach was 10% more accurate than cutting-edge machine learning models. Critically, Paradigm’s OpenAI partnership required 90% less expert clinician time. Paradigm’s use of GPT-4 and natural language, dramatically improved the evaluation of patient medical records and has the potential to scan hundreds of patients per minute, compared with research coordinators and healthcare professionals who can manually screen 50 patients per day. These clinical trial efficiencies will enable healthcare workers to spend more time on patient care and significantly accelerate patient enrollment.</p><p>Paradigm is building an end-to-end clinical trial platform that is being adopted by healthcare networks across the world to enable equitable access to clinical trials for all patients, while enhancing trial efficiencies and reducing burnout and paperwork for healthcare providers. These new partnerships are a testament to deploying machine learning advances and technological solutions to the most pressing issues in the healthcare industry — accelerating clinical trials with the goal of delivering new therapies to patients quicker. #clinicaltrials #healthcareinnovation</p><p>Christine Aylward &amp; Jillian Shaw, Magnetic Ventures</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=84ab0f2c3568" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Relation Therapeutics Announces Landmark Partnership with GSK to Identify Targets for Fibrotic…]]></title>
            <link>https://medium.com/@c_aylward/relation-therapeutics-announces-landmark-partnership-with-gsk-to-identify-targets-for-fibrotic-88ad3b5c77dc?source=rss-93033e4b53e7------2</link>
            <guid isPermaLink="false">https://medium.com/p/88ad3b5c77dc</guid>
            <dc:creator><![CDATA[Christine Aylward]]></dc:creator>
            <pubDate>Wed, 11 Dec 2024 22:12:01 GMT</pubDate>
            <atom:updated>2024-12-12T19:16:59.089Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*BI8gpn5-8_MK7jMxtUoYAA.jpeg" /><figcaption>Sequencing Area of Relation’s Lab in London’s Knowledge Quarter</figcaption></figure><p><a href="https://www.relationrx.com/"><strong>Relation Therapeutics</strong></a><strong> Announces </strong><a href="https://www.globenewswire.com/news-release/2024/12/10/2994205/0/en/Relation-announces-two-strategic-collaborations-with-GSK-to-advance-therapeutics-for-fibrotic-diseases-and-osteoarthritis.html"><strong>Landmark Partnership</strong></a><strong> with </strong><a href="https://www.gsk.com/en-gb/"><strong>GSK</strong></a><strong> to Identify Targets for Fibrotic Diseases and Osteoarthritis, Firmly Cementing Relation’s Position as a Leader in the TechBio Sector.</strong></p><p><em>This sector-leading partnership underscores Relation’s incredible growth journey and is a testament to the power of Relation’s Lab-in-the-Loop platform and team.</em></p><p>At <a href="https://magneticvc.com/">Magnetic Ventures</a> we spend our days and nights thinking about the technology that will help deliver life saving therapies to patients sooner. ​​We fundamentally believe a drug discovery approach which integrates patient-derived datasets, genetic perturbation studies, and machine learning has the potential to dramatically accelerate the discovery of novel drug targets and represents one of the greatest opportunities for value creation in biotech. In 2021, when Relation had three employees we led their Seed financing because we had high conviction for Relation’s mission to fuse experimental biology and machine learning and for Relation’s team, which includes world class scientists and drug discoverers. Now 70 employees strong, Relation has emerged as a global leader in TechBio generating world-class datasets and applying generative AI to design new molecules for targeted therapies, and executing two blockbuster deals with GSK.</p><p>Relation will receive an upfront payment of $45 million, which includes an equity investment of $15 million. In addition, Relation will be eligible to receive success-based collaboration payments of up to $63 million, and potential preclinical, development, commercial, and sales milestone payments averaging $200 million per target across both deals, as well as tiered royalties on net sales of products. <strong>This is the largest deal for a seed stage TechBio company </strong>as far as we know and is a testament to the power of Relation’s <a href="https://www.relationrx.com/science">Lab-in-the-Loop </a>platform and to the relentless work of Relation’s mission-driven team. It also adds another strategic investor in addition to <a href="https://www.google.com/search?client=safari&amp;rls=en&amp;q=nvidia&amp;ie=UTF-8&amp;oe=UTF-8">NVIDIA’s</a> NVentures who co-led a Seed extension with <a href="https://www.dcvc.com/">DCVC</a>, who also led the original seed extension. Magnetic has participated in each round due to our unwavering conviction for the technology and team.</p><p>GSK saw in Relation what Magnetic saw, as echoed in their announcement. <em>“Working with Relation enables us to gain deep and precise insights into human causal biology and apply these to therapeutic discovery through a data-driven approach, supported by Relation’s proprietary platform,” said Kaivan Khavandi, SVP, Global Head of Respiratory/Immunology R&amp;D at GSK. “The resulting targets will be supported by robust translational packages, which will in-turn provide clarity on deployment in early clinical evaluation, ultimately supporting our broader portfolio ambition to develop new medicines for fibrotic diseases and osteoarthritis –where there remains significant unmet medical need”.</em></p><p>Relation’s success is predicated on the unique integration of several tenets: (1) multi-modal patient data, (2) perturbation studies that use multi-dimensional ‘-omics data’ as a readout (e.g. single cell sequencing to understand the transcriptional profile of genes), (3) machine learning, (4) cellular models that accurately recapitulate the disease being studied, and (5) high-performance experimental design and vast quantities of computational firepower. A huge advantage of Relation’s approach is the use of human genetics and their proprietary atlas of data generated directly from patient tissue. The team has built a compelling map of the underlying disease biology of osteoarthritis.</p><p>In this partnership with GSK, the team combines Relation’s strengths of using machine learning in pursuit of understanding the root cause driving disease, with GSK’s global scale and tremendous expertise in developing therapies for patients. Through this partnership, the team at Relation is minimizing the risk of clinical failures by ensuring their targets are rigorously evaluated both experimentally and using cutting-edge computational assessments before entering the clinic.</p><p><strong>When we first </strong><a href="https://magneticvc.com/blog/posts/why-we-invested-in-relation-therapeutics-technology-and-team/"><strong>wrote about Relation we stressed technology and team</strong></a><strong>.</strong> <strong>To see what the team has accomplished in less than four years is more than impressive, it’s inspirational. </strong>In a relatively short period of time, Relation created Osteomics — the world’s largest single-cell atlas of the bone. This enabled the team to deeply characterize patient samples using single cell sequencing, proteomics, imaging, spatial genomics, and the clinical phenotypes of the patients themselves. By combining this information in one resource, the team uncovered new biology, therapeutic targets, biomarkers and the relevant patient subgroups who would benefit from their drug discovery approach.</p><p>The team has strategically focused on diseases where their drug discovery platform can be applied to opportunities where there is a well-validated path to the clinic, as demonstrated by this most recent partnership with GSK. Osteoarthritis is a debilitating degenerative joint disease that occurs when the cartilage and tissues in a joint break down. Millions of patients suffer from this painful condition and new treatments are essential.</p><p>The Relation team is quick to remind one another, “the patient is waiting.” This ethos is ever-present and we couldn’t be more delighted to be a partner alongside the other investors supporting Relation on its journey to deliver new therapies to patients sooner. #thepatientiswaiting</p><p>Christine, Jillian &amp; Umut</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=88ad3b5c77dc" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Our Recent Investment in Weave Bio: Deploying Generative AI to Accelerate the Delivery of New…]]></title>
            <link>https://medium.com/@c_aylward/our-recent-investment-in-weave-bio-deploying-generative-ai-to-accelerate-the-delivery-of-new-1758b55679de?source=rss-93033e4b53e7------2</link>
            <guid isPermaLink="false">https://medium.com/p/1758b55679de</guid>
            <category><![CDATA[ai]]></category>
            <category><![CDATA[drug-development]]></category>
            <category><![CDATA[genai]]></category>
            <category><![CDATA[pharmaceutical]]></category>
            <dc:creator><![CDATA[Christine Aylward]]></dc:creator>
            <pubDate>Mon, 01 Jul 2024 16:34:31 GMT</pubDate>
            <atom:updated>2024-12-14T00:12:17.638Z</atom:updated>
            <content:encoded><![CDATA[<h3>Our Recent Investment in Weave Bio: Deploying Generative AI to Accelerate the Delivery of New Therapies to Patients by Streamlining the Regulatory Process</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*VZbdgJ2X_KLCZLFRTKIFdw.jpeg" /><figcaption>Description: Chemist Lee Geismar, who was part of the team that reviewed the new drug application for thalidomide in the early 1960s, is shown some years later poring over several volumes of another application. Image Source: <a href="https://www.fda.gov/">https://www.fda.gov/</a></figcaption></figure><p>Delivering new therapeutics to patients is no easy or simple task. It requires multiple steps, coordination of numerous different disciplines and years of research, development, testing, and multiple regulatory steps. While the process begins in the laboratory, a crucial step to bringing new therapeutics to market is testing these candidates in humans. To do this, companies must submit and receive approval from the Food and Drug Administration (FDA) for an <a href="https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application">Investigational New Drug Application</a>(IND) — the first arduous regulatory hurdle in a long, resource-intensive journey.</p><p>One of the main challenges in IND submissions is the requirement for extensive documentation and coordination amongst multiple disciplines and departments. The submission includes detailed information on the target therapeutic’s chemical composition, proposed clinical trial design, manufacturing information, and the safety and efficacy data from preclinical studies. Think of 100s of thousands of documents from multiple different departments which need to be reviewed, analyzed, and summarized — a process, which is labor-intensive, costly, and can be prone to errors. And a process we believe will be vastly improved with advanced technology, which is why we co-led with <a href="https://www.innovationendeavors.com/">Innovation Endeavors</a>, the Seed financing for <a href="https://www.weave.bio/">Weave Bio</a>, a generative AI company which is tackling this problem; a problem that impacts every single therapeutics company, regardless of size, stage, modality, or disease area.</p><p>Weave has created the first digital platform, AutoIND, which uses generative AI, specifically Large Language Models (LLM), and knowledge graphs to manage and organize IND studies, draft sections, create tables, streamline and automate reviews, update drafted documents whenever the source files change, link and track every statement to specific sentences in the source files, and facilitate collaboration among colleagues. While conventional IND preparation processes can take more than a year, AutoIND produces a first draft of an IND in a single day and can reduce the overall time it takes to produce a final IND submission by well over 50%, returning capacity to regulatory teams, lowering costs, and ultimately decreasing the time it takes to deliver new therapies to patients. For an industry which submits approximately 1,500 INDs annually, AutoIND has the potential to transform the regulatory process.<br> <br>This is particularly urgent today. The industry is at a critical crossroads, facing both unprecedented challenges and opportunities. Since 2000, R&amp;D spending has exceeded $3.4 trillion. The average cost per successful New Molecular Entity (NME) has increased from $800 million in 2000 to $3.1 billion in 2022. In addition, the industry is grappling with a “patent cliff” challenge — the expiration of drug patents and the flood of generic alternatives — which is estimated to threaten more than $200 billion in annual revenue by 2030. <br> <br>The Inflation Reduction Act (IRA) has further intensified these challenges with reforms, which impose pricing caps and penalties on drugs whose costs exceed inflation metrics. These pressures, coupled with the persistent unmet needs of patients — diseases such as Alzheimer’s, Parkinson’s, and countless others remain without cures, underscore the urgency to bring new therapeutics to market quicker. <br> <br><a href="https://magneticvc.com/">Magnetic’s</a> founding investment thesis was that technology will impact every part of the healthcare ecosystem, and our seed investment in Weave extends our investment in the sector beyond drug discovery, clinical trials and manufacturing, to regulatory and processes.</p><p>Healthcare is incredibly complex and technology start-ups looking to solve problems in this complex sector require multidisciplinary teams. Weave was co-founded by Magnetic’s Venture Partner, <a href="https://www.linkedin.com/in/umuteser">Umut Eser</a> (AI/ML expert) and <a href="https://www.linkedin.com/in/aricaroline">Ari Caroline</a> the broader senior team <a href="https://www.linkedin.com/in/brandon-james-rice/">Brandon Rice</a> (CPO), and <a href="https://www.linkedin.com/in/lindsay-mateo-mba-72aa5b12/">Lindsay Mateo</a> (CCO).</p><p>Weave’s solution is poised to deliver unmatched value to pharma and biotech companies, significantly cut costs, and rapidly accelerate the delivery of groundbreaking drugs to patients. This is just the starting point for Weave. We believe Weave’s technology has the potential to improve the entire regulatory cycle and move beyond regulatory to other process-heavy areas in healthcare, such as asset life cycle management. We know change is on the horizon and we are excited to continue to work with Innovation Endeavors and the Weave team to help realize the profound potential of Weave’s important technology.</p><p>Christine Aylward<br>Founder &amp; Managing Partner</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=1758b55679de" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Relation Therapeutics: Revolutionizing Drug Development & the Impact of AI and DeepTech on the…]]></title>
            <link>https://medium.com/@c_aylward/relation-therapeutics-revolutionizing-drug-development-the-impact-of-ai-and-deeptech-on-the-8fd3f256f477?source=rss-93033e4b53e7------2</link>
            <guid isPermaLink="false">https://medium.com/p/8fd3f256f477</guid>
            <dc:creator><![CDATA[Christine Aylward]]></dc:creator>
            <pubDate>Fri, 15 Mar 2024 21:38:19 GMT</pubDate>
            <atom:updated>2024-03-15T21:38:19.087Z</atom:updated>
            <content:encoded><![CDATA[<p><a href="https://www.relationrx.com/"><strong>Relation Therapeutics</strong></a><strong>: Revolutionizing Drug Development &amp; the Impact of AI and DeepTech on the Future of Medicine</strong></p><p><strong><em>In 1983 polymerase chain reaction (PCR) was discovered. In 2003, scientists produced the first sequence of the human genome. By 2012, CRISPR editing arrived on the scene, allowing for efficient gene editing. More than ten years later in 2023 we saw the landmark approval of the first CRISPR therapy.</em></strong></p><p>Just as the discoveries of PCR and CRISPR marked transformative milestones for science and society, the recent years have been defined by the groundbreaking advancements in generative artificial intelligence (AI) and <a href="https://www.nvidia.com/en-us/glossary/large-language-models/">large language models</a> (LLMs). In 1950, Alan Turing published his influential essay, “Computing Machinery and Intelligence” where he imagined the possibility of computers created to simulate intelligence and machines capable of learning. AI has changed dramatically since the days of Alan Turing, and the growth over the past two years indicates that a positive impact on drug development and human health will <strong><em>not</em></strong> take a decade. In fact, it’s already happening at Magnetic portfolio company <a href="https://www.relationrx.com/">Relation Therapeutics</a> and beyond.</p><p>Relation represents a new path to drug discovery and a new breed of Techbio companies focused on deploying technology to drive innovation in life sciences. Where biotech companies prioritize de-risked areas of biology, Techbio uses computation, massive datasets, machine learning (ML) algorithms, and AI to prioritize best case outcomes with the highest likelihood of data-driven success.</p><p>Magnetic led Relation’s initial seed financing in 2021 and has witnessed the company’s impressive progress, including the build out of its technology platform, opening of it’s wet /dry laboratory in London’s Knowledge Quarter, and the launch of Osteomics, a clinical observation study to create the world’s largest functional, single-cell bone atlas derived from human patient tissue. Today we celebrate their $35M of new financing led by DCVC and co-led by N Ventures, NVIDIA’s investment arm with participation from ARK Invest, Deerfield Management and existing investors Magnetic, Kholsa, and Abcam founder Jonthan Milner, among others.</p><p><strong>Drug Discovery: Today’s Challenges</strong></p><p>In the vast and complex landscape of drug development, the promise of exponential growth akin to that of information technologies has remained largely unfulfilled. Instead, the industry has witnessed an inverse trend, where the costs associated with developing new therapeutic solutions have soared to $2B per target. Traditional approaches of drug discovery and development are marred by inefficiencies and a lack of predictability. The process has predominantly relied on blind subject screening, uninformed trial-and-error methods, and a qualitative understanding of biology, which not only extend the timeframes and elevate the costs but also diminish the probabilities of success, as evident by the 90% failure rate.</p><p><strong><em>These statistics are unimaginable in a world where technology has revolutionized the way we communicate, shop, travel, and most other aspects of life.</em></strong></p><p>The rapid development of OpenAI’s LLMs, from GPT2 in 2019 to GPT4 in a span of just more than three years, exemplifies the exponential pace of technological innovation, a trend now poised to revolutionize the biotech sector. This leap forward, marked by the integration of AI, omics, and single-cell sequencing, heralds a new era in drug development. Magnetic’s founding investment thesis was that these technologies would impact and improve every aspect of healthcare. Our commitment is fueled by the potential to transform drug discovery and development, mirroring ChatGPT’s record-setting growth trajectory. We believe Relation, known for its “<a href="https://endpts.com/relation-raises-35m-with-nvidia-and-deerfield-backing-for-computational-drug-discovery/">ChatGPT-like</a>” predictive capabilities in DNA analysis, is poised to be a pioneer.</p><p><strong>Relation Therapeutics</strong></p><p>Relation is as a prime example of innovation in action, embracing a lab-in-the-loop strategy that harnesses predictive and generative AI to map out relational graphs spanning the entire spectrum of biomedical knowledge. Their approach, from unraveling molecular insights to decoding phenotypic nuances, facilitates the generation, analysis, and interpretation of human data, shedding new light on the behaviors of genes, cells, and tissues. This is particularly pivotal in tackling diseases such as osteoporosis, the company’s first area of focus, which has been devoid of novel therapeutic breakthroughs for more than three decades.</p><p>Central to Relation’s ethos is the principle that patient welfare should dictate the direction of discovery efforts. By leveraging human genetics and proprietary multi-omics datasets derived directly from patient tissues, the team crafts detailed maps of disease biology and cellular disease models, enriching our understanding of clinical phenotypes. Relation excels in its application of high-performance experimental and computational techniques. This includes marrying target validation with advanced methods such as spatial transcriptomics, sequencing, and tissue profiling. A key to their success has been a strategic alliance with NVIDIA, leveraging its hyperscale computing capabilities to enhance their leading-edge machine learning platforms.</p><p>Building such transformative companies is an intricate process and an art, which requires assembling a <a href="https://www.relationrx.com/about#partners">team</a> of biologists with an intimate understanding of disease mechanisms, and computer scientists skilled in the nuances of advanced technology and machine learning. As we wrote in our <a href="https://medium.com/p/b78a7ef9e642">first post regarding Relation</a> and witnessed the past several years working closely with the Relation team, they exemplify this harmonious integration. We couldn’t be prouder to partner with the Relation team.</p><p>Relation’s mission is to revolutionize drug development, always with the patient’s needs at the forefront. This commitment is echoed in the broadened perspective that AI offers a bridge across biology’s diverse scales, from molecular intricacies to single-cell omics and disease phenotypes, moving towards a more quantitative understanding of biology.</p><p>We’ve never been more excited about the opportunity to accelerate drug discovery, deliver new therapies to patients quicker, and improve overall patient care — this is what makes us so excited to work with Relation and our co-investors. As Relation says, the patient is waiting.</p><p><a href="https://magneticvc.com/team/">The Magnetic Team</a></p><p>Christine Aylward, Jillian Shaw, Ph.D, Umut Eser, Ph.D.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=8fd3f256f477" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Why we invested in Relation Therapeutics: technology and team.]]></title>
            <link>https://medium.com/@c_aylward/why-we-invested-in-relation-therapeutics-technology-and-team-b78a7ef9e642?source=rss-93033e4b53e7------2</link>
            <guid isPermaLink="false">https://medium.com/p/b78a7ef9e642</guid>
            <category><![CDATA[healthcare-technology]]></category>
            <category><![CDATA[drug-development]]></category>
            <category><![CDATA[data-science]]></category>
            <category><![CDATA[drug-discovery]]></category>
            <category><![CDATA[machine-learning]]></category>
            <dc:creator><![CDATA[Christine Aylward]]></dc:creator>
            <pubDate>Wed, 29 Jun 2022 16:30:20 GMT</pubDate>
            <atom:updated>2022-06-29T16:30:20.540Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/938/1*kbqz0gayDbfY6KkHS0AxBw.png" /></figure><p>I founded <a href="https://magneticvc.com/">Magnetic Ventures</a> in 2018 with the fundamental investment thesis that we are at the dawn of the second golden age of healthcare, driven by the convergence of technology and biology. We believe technology tools including artificial intelligence (AI) and machine learning (ML), combined with omics are enabling us to understand the biology of disease in ways previously unimaginable and have the potential to transform drug discovery and development.</p><p>It’s estimated that a novel therapeutic requires a minimum of $1B of funding (The Tufts Center for the Study of Drug Development estimates this number is closer to $2.5B) and 10+ years of development to achieve FDA approval. Despite this investment, less than 10% of targets entering clinical trials ultimately receive FDA approval.</p><p>This is the problem <a href="https://www.relationrx.com/">Relation Therapeutics</a> is on a mission to solve.</p><p>Relation combines patient tissue-derived atlases of disease at single-cell resolution, functional genomics, and graph ML to prioritize interventions with the greatest likelihood of combating disease mechanisms. Drawing on advances in experimental feedback systems, their “Lab-in-the-Loop” enables the ML to make predictions from complex datasets in order to parse the most important information for understanding the problem itself.</p><p>Every year, the resolution of high-dimensional molecular probing (omics) to the human body and the amount of data generated are exponentially increasing. In parallel is the accelerated development of techniques required to learn meaningful representations from complex data (AI, deep learning, ML). Applying these techniques to integrated multi-modal biomedical data leads to an unprecedented understanding of human disease biology.</p><p>Relation’s platform applies a specific type of ML, graph ML, a technology best known for its application to recommendation systems used by companies such as Twitter, Netflix, and Google Earth. Everyone has seen a version of “since you bought/watched/liked this, you may want to consider buying/watching/liking these items next” — why not apply this to drug discovery? These recommendation systems are successful in other domains for two primary reasons: 1) the amount of data, and 2) representation learning on graphs. Now imagine you apply this insight to biology: “since you have already successfully tested these molecules/targets, you may want to try these molecules/targets next.” Relation has the tools in place to understand a previously insurmountable number of combinatorial functional relationships between genes, proteins, and therapeutic compounds, which we believe will dramatically increase the probability of success in drug discovery.</p><p>As early-stage investors, we make bets not only on category-defining technological innovation, but also, and equally as important, on teams. When a founder we know and respect calls with an idea we pay attention. Relation co-founder and Board Chair Charlie Roberts is someone I have known and deeply respected for close to 15 years. When Charlie called about Relation, I jumped at the opportunity to learn more.</p><p>It is extremely hard to find a team that rivals Relation’s expertise in mechanistic biology, drug discovery, and proficiency in ML. The <a href="https://endpts.com/exclusive-pfizer-vet-grabs-25m-seed-round-to-integrate-machine-learning-genomics-tech-in-drug-rd/">team</a> is led by CEO Dr. David Roblin: the former head of R&amp;D and CMO of Pfizer Europe and includes CTO Dr. Lindsay Edwards: the former VP of AI at AstraZeneca and VP of ML at GSK. In addition, the Scientific Advisory Board is world class from institutions including Stanford, The Broad Institute of MIT and Harvard, Imperial College of London, and Oxford.</p><p>We believe Relation has the ideal recipe of technology and team to become a pioneer in data-driven drug discovery. We are proud to be partners to the team as they execute their mission to decode and modulate biology to cure disease, faster and with greater certainty, and to transform the discovery and development of new medicines.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=b78a7ef9e642" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>